Singapore markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
776.75-4.35 (-0.56%)
At close: 04:00PM EDT
774.15 -2.60 (-0.33%)
Pre-market: 06:59AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close781.10
Open774.76
Bid773.00 x 1200
Ask775.50 x 1100
Day's range768.25 - 782.60
52-week range419.80 - 800.78
Volume2,762,271
Avg. volume3,116,267
Market cap738.227B
Beta (5Y monthly)0.37
PE ratio (TTM)114.90
EPS (TTM)6.76
Earnings date30 Apr 2024
Forward dividend & yield5.20 (0.67%)
Ex-dividend date14 Feb 2024
1y target est838.74
  • Barrons.com

    Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock’s Falling.

    The Danish pharmaceutical giant, which became Europe’s most valuable company last year, said Wegovy sales jumped 106% in the first quarter.

  • Reuters

    UPDATE 6-Blockbuster obesity drug demand drives Novo Nordisk profit boost

    Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Jyske Bank said the beat and upgrade were driven by a one-off U.S. sales adjustment, while underlying growth was a bit weaker than expected. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.

  • Reuters

    Blockbuster obesity drug demand drives Novo Nordisk profit boost

    Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before Thursday's earnings, on the back of Wegovy's popularity.